Offers?

Discussion in 'Greenwich Biosciences' started by anonymous, Jun 18, 2018 at 8:49 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Wait till you see what we can do. So happy to be here.
     

  2. anonymous

    anonymous Guest

    diversity hire in St. Louis, guy has been average at every job, could not sell ALS drug so jumped ship to try it here, will be average again and probably leave in two years. three candidates with Epilepsy relationships passed over, sad state of affairs today
     
  3. anonymous

    anonymous Guest

    St. Louis sucks for most new drug launches anyway. The docs are afraid to try anything new until the rest of the country has been doing it for years and it’s listed as standard of care in a twenty year old text book.

    KC drives new product use in Missouri
     
  4. anonymous

    anonymous Guest

    diversity manager also in the Midwest:rolleyes:
     
  5. anonymous

    anonymous Guest

    Question: when will the stock price stop falling?
    Answer: when Charlotte’s Web and Haley’s Hope are blocked from the market.
     
  6. anonymous

    anonymous Guest

    Let me get this right. You are hoping CW and HH will be ‘blocked’ so you can make money on your stock options. Do you really care about the kids!!!!! And I bet you sold the “it’s all about the patient” in your interview. You are a very selfish person.
     
  7. anonymous

    anonymous Guest

    HH and CW are not competitors to Epidiolex. Also parents who think these formulations do not have side effects are kidding themselves. Doctors will prescribe FDA approved medications in most cases.

    The value of GW is not Epidiolex it is the pipeline and future indications. Epidiolex sales are already factored into evaluation. Short term Epidiolex sales are going to be amazing 1100 patients coming off of compassionate use and convertes by January is as many patients who are on Banzel currently and close to the sales of Aptium and Briviat.

    If two or three of the pipeline indications happen this company has a long and bright future or will be acquired. Either way stock goes up.
     
  8. anonymous

    anonymous Guest

    So all 1100 compassionate care patients have a diagnosis of Dravet or LGS. Maybe 50% so the remaining will get free drug cuz insurance will deny off-label. What are you smoking?!?
     
  9. anonymous

    anonymous Guest

    They are on medication seizure free and in several cases more than a year. My guess is it will be payed for.
     
  10. anonymous

    anonymous Guest

    Yes, these patients will easily move through he PA/Step process. All boxes have already been checked.
     
  11. anonymous

    anonymous Guest

    Except for the ICD-10 diagnosis box. Expanded access patients do not have PA/Step process as there was no benefit verification/insurance payer involved. Wait for payer request for medical records to confirm diagnosis. Offices are going to have lots of questions. Ooops.....not Dravet or LGS. I hope I’m wrong but trying to be realistic as we launch.
     
  12. anonymous

    anonymous Guest

    I guarantee you they all have failed multiple AEDs. Therefore step requirement checked. If they are refractory and the documentation is proper, they will be fine.
     
  13. anonymous

    anonymous Guest

    Of course they have failed many AED’s. BUT far less than 50% of Expanded Access patients with on-label diagnosis. There in lies the challenge
     
  14. anonymous

    anonymous Guest

    Heard he won Pclub at his last job for ALS. Sounds like you got passed over buddy.